Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells <i>in vitro</i> and <i>in vivo</i>
Le Xiong, Xiao-Min Lin, Jun‐Hua Nie, Hai‐Shan Ye, Jia Liu
Abstract
Background: Docetaxel and doxorubicin combination has been widely used in anaplastic thyroid cancer/ATC treatment but often results in serious adverse effects and drug resistance. Resveratrol effectively inhibits ATC cell proliferation in vitro without affecting the corresponding normal cells, while its in vivo anti-ATC effects especially on the ones with docetaxel/doxorubicin-resistance have not been reported due to its low bioavailability. Nanoparticles with sustained-release and cancer-targeting features may overcome this therapeutic bottleneck.
Topics & Concepts
DocetaxelResveratrolDoxorubicinIn vivoPharmacologyMedicineAnaplastic thyroid cancerApoptosisCancerCancer researchChemotherapyThyroid cancerInternal medicineChemistryBiologyBiochemistryBiotechnologySirtuins and Resveratrol in MedicineCancer-related Molecular PathwaysPARP inhibition in cancer therapy